Skip to main content

ERRATUM article

Front. Immunol., 14 March 2023
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1178295

Erratum: CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity

This article is an erratum on:

  1. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.

By Baumgaertner P, Schmidt J, Costa-Nunes C-M, Bordry N, Guillaume P, Luescher I, Speiser DE, Rufer N and Hebeisen M (2022) Front. Immunol. 13:973986. doi: 10.3389/fimmu.2022.973986

An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Lausanne”.

The original version of this article has been updated.

Keywords: cancer immunotherapy, vaccine peptide, melan-A/MART-1, NY-ESO-1, peptide-HLA binding affinity, TCR-peptide-MHC affinity, human CD8 T cells

Citation: Frontiers Production Office (2023) Erratum: CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity. Front. Immunol. 14:1178295. doi: 10.3389/fimmu.2023.1178295

Received: 02 March 2023; Accepted: 02 March 2023;
Published: 14 March 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.